Before The Elf On The Shelf hit stores in 2005, it was a family tradition in Chanda Bell's family for decades. Now, more than 11 million elves have been adopted all around the world. Bell, the company's Founder and CEO, explains how she and her family turned their holiday tradition into a viral phenomenon. When Bell and her mother decided to publish the story behind their family tradition, they pitched it to a number of publishers. After getting turned down from every one they spoke with, they decided to publish the story themselves. Now, 13 years later, that story has become a Christmastime favorite for millions of children. Bell says that there were a number of challenges getting the company off the ground beyond taking on debt to fund it. Neither she nor her mom or sister had business backgrounds, but Bell says they learned quickly.

Share:
More In Business
Poll: More Americans think companies benefit from legal immigration
A new poll finds U.S. adults are more likely than they were a year ago to think immigrants in the country legally benefit the economy. That comes as President Donald Trump's administration imposes new restrictions targeting legal pathways into the country. The Associated Press-NORC Center for Public Affairs Research survey finds Americans are more likely than they were in March 2024 to say it’s a “major benefit” that people who come to the U.S. legally contribute to the economy and help American companies get the expertise of skilled workers. At the same time, perceptions of illegal immigration haven’t shifted meaningfully. Americans still see fewer benefits from people who come to the U.S. illegally.
Tylenol maker rebounds a day after unfounded claims about its safety
Shares of Tylenol maker Kenvue are bouncing back sharply before the opening bell a day after President Donald Trump promoted unproven and in some cases discredited ties between Tylenol, vaccines and autism. Trump told pregnant women not to use the painkiller around a dozen times during the White House news conference Monday. The drugmaker tumbled 7.5%. Shares have regained most of those losses early Tuesday in premarket trading.
Load More